Perinatal HIV prevention, prophylaxis, and infant feeding
Preventing HIV transmission during pregnancy, birth, and breastfeeding depends on coordinated care rather than a single medicine or decision. Maternal antiretroviral therapy, viral-load monitoring, delivery planning, newborn prophylaxis, and an appropriate feeding plan work together to reduce the possibility of perinatal and postnatal infection.
The central aim is to keep the mother’s viral load suppressed throughout pregnancy and after delivery while ensuring that the infant receives timely testing and, when indicated, antiretroviral protection. Feeding choices must be considered within the local health system, including access to safe water, reliable formula supplies, lactation support, and follow-up testing.
These issues were relevant to the scientific discussions planned for the FAOPS 2020 congress, which was scheduled to bring together specialists in perinatal and neonatal medicine in Tokyo before cancellation during the COVID-19 pandemic. The clinical principles remain important for current practice and research.
How transmission occurs
HIV can pass from a mother to her infant during pregnancy, labor, delivery, or breastfeeding. The likelihood is influenced by maternal viral load, the timing and consistency of antiretroviral treatment, the condition of the placenta and birth canal, obstetric events, and whether the infant is exposed to breast milk containing virus.
The most influential modifiable factor is sustained maternal viral suppression. Starting combination antiretroviral therapy as early as possible reduces the amount of circulating virus and lowers the probability of transmission before birth and at delivery. Treatment also protects the mother’s long-term health, which is essential for safe pregnancy care and continued family support.
A detectable viral load late in pregnancy may require an adjusted delivery plan, additional adherence support, resistance testing, or a change in the treatment regimen. Decisions should be based on current laboratory results and national or regional protocols rather than on a single result from early pregnancy.
Maternal antiretroviral treatment
Pregnant people living with HIV should receive a fully suppressive combination regimen recommended by current specialist guidance. Many widely used medicines have reassuring pregnancy safety data, while others may require particular timing, dose, or monitoring considerations. The choice must account for previous treatment, drug resistance, kidney and liver function, co-infections, drug interactions, and the patient’s ability to take medication consistently.
Adherence counseling should be practical and nonjudgmental. Nausea, changing work schedules, fear of disclosure, depression, unstable housing, and medication access can all interfere with treatment. A care team can help by simplifying dosing, arranging refills, treating side effects, and connecting the patient with social and mental-health services.
Viral-load testing is a key part of antenatal surveillance. Results near delivery help clinicians estimate residual transmission risk and determine whether additional intrapartum measures or infant prophylaxis are warranted. After birth, maternal therapy normally continues, because stopping treatment can cause viral rebound and harm the mother even when the immediate goal of preventing infant infection has been achieved.
Newborn prophylaxis and diagnostic follow-up
An HIV-exposed newborn should receive antiretroviral prophylaxis as soon as possible after birth, ideally within the first hours of life. The duration and intensity of the regimen depend on the estimated transmission risk. An infant whose mother maintained viral suppression may receive a standard course, while higher-risk exposure can require more than one medicine and a longer period of protection.
The exact protocol differs by country and may change as evidence develops. Clinicians consider maternal treatment history, viral load close to delivery, possible drug resistance, delivery circumstances, and whether breastfeeding is planned. Neonatal dosing must be weight-based, accurately documented, and explained to caregivers before discharge.
Virologic testing uses an HIV nucleic acid test rather than relying on antibody testing alone, because maternal antibodies can remain in an infant’s blood for many months. Testing schedules vary according to exposure risk and feeding method. A positive result requires urgent specialist review and confirmatory testing, while a negative early result does not necessarily end follow-up.
| Clinical situation | Main prevention focus | Follow-up priorities |
|---|---|---|
| Maternal viral load suppressed near delivery | Continue effective maternal therapy and provide newborn prophylaxis according to local guidance | Infant virologic testing, medication adherence, and routine pediatric care |
| Maternal treatment started late or viral load remains detectable | Review adherence, resistance, regimen effectiveness, and delivery planning | Enhanced newborn prophylaxis and expedited specialist follow-up |
| Breastfeeding in a setting that supports it | Maintain maternal suppression and provide structured counseling | Regular maternal viral-load checks and infant HIV testing |
| Replacement feeding is safe, acceptable, feasible, affordable, and sustainable | Avoid breast-milk exposure while ensuring adequate nutrition | Formula preparation education and routine growth monitoring |
| Missed newborn doses or uncertain exposure history | Contact an HIV and pediatric specialist promptly | Reconstruct timing, assess risk, and arrange testing without delay |
Infant feeding and HIV risk
Infant feeding recommendations cannot be separated from local conditions. In settings where safe replacement feeding is consistently available and prepared with clean water, exclusive formula feeding may eliminate breast-milk exposure. In many communities, however, formula feeding may bring serious risks from unsafe water, insufficient supply, stigma, cost, or early mixed feeding.
Where breastfeeding is recommended or chosen under a supported public-health program, the safest approach is generally exclusive breastfeeding for the advised period rather than combining breast milk with other foods or liquids too early. Mixed feeding can increase intestinal inflammation and may raise the chance of HIV transmission, especially before the infant’s gut has matured.
Maternal antiretroviral therapy with sustained viral suppression substantially lowers transmission during breastfeeding, but it does not make the risk zero. Breastfeeding plans should include regular viral-load monitoring, support for exclusive feeding, prompt assessment of breast problems such as mastitis or cracked nipples, and rapid action if maternal treatment is interrupted or viral load becomes detectable.
The decision should be individualized through shared counseling. A parent’s informed preference matters, but counseling must also explain the safety of each available option, the practical demands of preparation, and the need for ongoing testing. Advice should avoid stigma and should not assume that one feeding method is equally safe in every household.
Nutrition, development, and family-centered care
HIV prevention is part of a broader perinatal health strategy. Adequate maternal nutrition, treatment of anemia and infections, mental-health support, and access to antenatal care can influence treatment continuity and infant outcomes. Nutrition counseling should address the mother’s health without suggesting that supplements or special diets can replace antiretroviral therapy.
Research into early-life nutrition also examines how prenatal conditions may shape later metabolic and developmental health. Readers interested in the relationship between maternal nutrition and long-term biology can explore epigenetic programming research, while keeping in mind that emerging findings do not replace established HIV prevention measures.
Family-centered care helps translate clinical recommendations into daily routines. Caregivers need clear instructions about medicine storage, dosing devices, missed doses, clinic appointments, and signs of illness. When safe disclosure is possible, involving a trusted family member can provide practical support, although confidentiality and protection from discrimination must remain priorities.
Neonatal teams should also coordinate with obstetric clinicians, infectious-disease specialists, pharmacists, lactation professionals, social workers, and primary-care providers. This collaboration reduces conflicting advice and makes it more likely that maternal and infant records, laboratory results, prescriptions, and referrals will be completed on time.
Practical priorities for clinical teams and families
Evidence-based care is most effective when it is organized before labor begins. Every maternity service should have a clear pathway for identifying HIV exposure, obtaining maternal viral-load results, prescribing newborn prophylaxis, arranging infant testing, and ensuring follow-up after discharge.
Care teams can use the following priorities:
- Start or continue effective combination antiretroviral therapy as early as possible and review adherence at every visit.
- Measure maternal viral load near delivery and document the result where the obstetric and newborn teams can access it.
- Give the infant the recommended prophylaxis promptly, with weight-based dosing and written caregiver instructions.
- Create a feeding plan that reflects HIV risk, local policy, household resources, water safety, and the parent’s informed preference.
- Arrange a dated schedule for infant virologic testing, medication review, growth assessment, and maternal follow-up.
Communication should be direct and compassionate. Terms such as “high risk” should describe a clinical situation, not assign blame. A missed dose, late diagnosis, or detectable viral load calls for rapid support and reassessment rather than criticism, because shame can make future engagement with care less likely.
Keeping prevention continuous after birth
The postpartum period can be clinically and socially demanding. Sleep deprivation, recovery from delivery, financial pressure, and changes in insurance or clinic access may disrupt maternal treatment. Before discharge, the care team should confirm medication supplies, follow-up appointments, contact information, transportation options, and a plan for urgent questions.
Infant HIV testing is a process, not a single appointment. Results should be reviewed with the caregiver, and the testing plan should account for whether the infant receives breast milk, whether prophylaxis was completed, and whether any new maternal risk has emerged. Routine immunizations, growth monitoring, and developmental care should continue alongside HIV-related follow-up.
Long-term prevention also includes reproductive counseling. People living with HIV should be offered respectful information about contraception, future pregnancy planning, sexually transmitted infection prevention, and treatment options that support health before conception. A suppressed viral load benefits the parent, the current infant, and future reproductive choices.
Clinics and public-health programs can strengthen outcomes by auditing missed tests, delays in prophylaxis, loss to follow-up, and feeding-related complications. Reviewing these measures reveals where systems fail families and supports better coordination between maternity wards, neonatal units, laboratories, pharmacies, and community services.
Use current national or international guidance to shape local protocols, and ensure that every HIV-exposed infant leaves care with medication instructions, testing appointments, and a realistic feeding plan. Early, respectful coordination gives families the strongest opportunity to protect infant health while maintaining the mother’s own treatment and wellbeing.
